Cannabidiol
- Generic Name
- Cannabidiol
- Brand Names
- Epidiolex, Sativex, Epidyolex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 13956-29-1
- Unique Ingredient Identifier
- 19GBJ60SN5
- Background
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...
- Indication
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...
- Associated Conditions
- Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
- Associated Therapies
- -
Investigation of the Pharmacokinetic Profile of CBD
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Hurd,Yasmin, Ph.D.
- Target Recruit Count
- 24
- Registration Number
- NCT05023070
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
- Target Recruit Count
- 160
- Registration Number
- NCT05016349
Cannabidiol (CBD) in Adults With ASD
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 40
- Registration Number
- NCT05015439
- Locations
- 🇺🇸
JHBMC, Baltimore, Maryland, United States
Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
- Conditions
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT04978428
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 40
- Registration Number
- NCT04878627
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
CBD for the Treatment of Alcohol Use Disorder
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 45
- Registration Number
- NCT04873453
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Effects of Cannabidiol (CBD) on the Brain
- Conditions
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Auburn University
- Target Recruit Count
- 15
- Registration Number
- NCT04831294
- Locations
- 🇺🇸
Auburn University MRI Research Center, Auburn, Alabama, United States
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04778644
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Sex Differences in Neural Response to Cannabidiol
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 19
- Registration Number
- NCT04777643
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.